Guideline-Endorsed Answers to Key Questions in Nontuberculous Mycobacterial Lung Disease Management

Get up to date with the experts on practice guidelines and how to provide individualized and comprehensive treatment plans in partnership with your patients with NTM-LD. Download slides, read ClinicalThought faculty commentaries, or explore the on-demand multimedia module from this engaging symposium.

Keira A. Cohen, MD
Program Director

David E. Griffith, MD

Princy N. Kumar, MD, FIDSA, MACP

On-Demand Webcast

Multimedia

Guideline-Endorsed Answers to Key Questions in Nontuberculous Mycobacterial Lung Disease Management

View Multimedia

Hear insights from 3 faculty experts as they engage in a lively discussion on guideline updates in the diagnosis, monitoring, and treatment of patients with nontuberculous mycobacterial lung disease.

Keira A. Cohen, MD
Program Director

David E. Griffith, MD

Princy N. Kumar, MD, FIDSA, MACP Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Pharmacists: 1.0 contact hour (0.1 CEUs) Released: November 19, 2021 Expired: No longer available for credit

Emergence of New Guidelines: NTM Lung Disease in 2021

How can we reduce the time to diagnosis of NTM-LD and linkage to care?

How do you decide to start (or not start) treatment for NTM-LD?

What do you monitor for and how often during NTM-LD treatment?

How do you approach treatment-refractory NTM-LD?